These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction. Weaver WD Eur Heart J; 1996 Sep; 17 Suppl E():14-20. PubMed ID: 11823998 [TBL] [Abstract][Full Text] [Related]
23. Clinical profile of saruplase: mortality and safety. Betriu A Int J Clin Pract Suppl; 1998 Nov; 99():16-20. PubMed ID: 10344036 [TBL] [Abstract][Full Text] [Related]
24. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs. Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007 [TBL] [Abstract][Full Text] [Related]
25. Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). Peters RJ; Spickler W; Théroux P; White H; Gibson M; Molhoek PG; Anderson HV; Weitz JI; Hirsh J; Weaver WD Am Heart J; 2001 Aug; 142(2):237-43. PubMed ID: 11479461 [TBL] [Abstract][Full Text] [Related]
26. Effect of changes in liver blood flow on the pharmacokinetics of saruplase in patients with acute myocardial infarction. van Griensven JM; Koster RW; Hopkins GR; Beier H; Günzler WA; Kroon R; Schoemaker RC; Cohen AF Thromb Haemost; 1997 Sep; 78(3):1015-20. PubMed ID: 9308746 [TBL] [Abstract][Full Text] [Related]
27. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Weaver WD Eur Heart J; 1996 Dec; 17 Suppl F():9-15. PubMed ID: 8960443 [TBL] [Abstract][Full Text] [Related]
28. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
29. [Different therapeutic regimens in thrombolysis of acute myocardial infarct]. Zeymer U; Neuhaus KL Z Kardiol; 1994; 83 Suppl 6():83-8. PubMed ID: 7863705 [TBL] [Abstract][Full Text] [Related]
30. Accelerated infusion of streptokinase in acute myocardial infarction results in better TIMI flow grade in infarct-related artery. Dwivedi SK; Saran RK; Narain VS; Bansal S; Gupta R; Puri VK Indian Heart J; 2000; 52(1):40-4. PubMed ID: 10820932 [TBL] [Abstract][Full Text] [Related]
31. The effect of taprostene in patients with acute myocardial infarction treated with thrombolytic therapy: results of the START study. Saruplase Taprostene Acute Reocclusion Trial. Bär FW; Meyer J; Michels R; Uebis R; Lange S; Barth H; Groves R; Vermeer F Eur Heart J; 1993 Aug; 14(8):1118-26. PubMed ID: 8404943 [TBL] [Abstract][Full Text] [Related]
32. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir). Schneider J; Wnendt S; Saunders D; Heinzel-Wieland R; Wilffert B; Steffens G Eur J Pharmacol; 1996 Apr; 302(1-3):69-77. PubMed ID: 8790994 [TBL] [Abstract][Full Text] [Related]
33. Thrombolysis or nothing for acute myocardial infarction? It's all the same! Bertele' V; Angelici L; Barlera S; Garattini S Br J Clin Pharmacol; 2008 Jun; 65(6):955-8. PubMed ID: 18384444 [TBL] [Abstract][Full Text] [Related]
34. Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA). Tatu-Chiţoiu G; Teodorescu C; Dan M; Guran M; Căpraru P; Istrăţescu O; Tatu-Chiţoiu A; Bumbu A; Chioncel V; Arvanitopol S; Dorobanţu M Rom J Intern Med; 2004; 42(3):557-73. PubMed ID: 16366130 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. Michels HR; Hoffman JJ; Bär FW J Thromb Thrombolysis; 1999 Oct; 8(3):213-21. PubMed ID: 10500311 [TBL] [Abstract][Full Text] [Related]
36. Thrombolytic therapy in acute myocardial infarction--selected recent developments. Bode C; Nordt TK; Runge MS Ann Hematol; 1994 Oct; 69(4):S35-40. PubMed ID: 7948298 [TBL] [Abstract][Full Text] [Related]
37. Hemostatic changes after thrombolytic therapy with saruplase (unglycosylated single-chain urokinase-type plasminogen activator) and urokinase (two-chain urokinase-type plasminogen activator). Michels HR; Hoffmann JJ; Windeler J; Hopkins GR Blood Coagul Fibrinolysis; 1996 Nov; 7(8):766-71. PubMed ID: 9034556 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Koster RW; Cohen AF; Hopkins GR; Beier H; Günzler WA; van der Wouw PA Thromb Haemost; 1994 Nov; 72(5):740-4. PubMed ID: 7534946 [TBL] [Abstract][Full Text] [Related]
39. Combinations of thrombolytic agents in acute myocardial infarction. Bode C; Baumann H; von Hodenberg E; Freitag M; Nordt T Z Kardiol; 1993; 82 Suppl 2():125-8. PubMed ID: 8328189 [TBL] [Abstract][Full Text] [Related]
40. Interactions of saruplase with acetylsalicylic acid, heparin, glyceryl trinitrate, tranexamic acid and aprotinin in a rabbit pulmonary thrombosis model. Schneider J Arzneimittelforschung; 1990 Oct; 40(10):1180-4. PubMed ID: 1705427 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]